Is Bristol-Myers Squibb Co. (BMY) One of the Best Companies in America?

Missed it by this much. That’s how it goes some times.

The Motley Fool recently published its list of The 25 Best Companies in America and while Bristol-Myers Squibb Co. (NYSE:BMY)made the initial cut down from 1,700 public companies to about 40, it failed to make the final cut.

For having such a long name and a history that dates back to 1858, Bristol-Myers Squibb is surprisingly smaller than most of its pharmaceutical peers. Quite a few younger big biotechs — Celgene Corporation (NASDAQ:CELG), Gilead Sciences, Inc. (NASDAQ:GILD), and Amgen, Inc. (NASDAQ:AMGN) — have market caps larger than Bristol-Myers.

Bristol Myers Squibb Co. (NYSE:BMY)While bigger is often better because it helps with profit margins, I like the smaller, more-focused Bristol Myers Squibb Co. (NYSE:BMY).

A few years ago, Bristol-Myers decided to slim down and focus exclusively on drug development. The company spun off its baby formula business, Mead Johnson Nutrition CO (NYSE:MJN), and sold off quite a few other auxiliary businesses while expanding its drug development through acquisitions to fill its pipeline.

That forward-thinking attitude has earned it a nomination for the Fool’s top 25 best-run companies.

The case for Bristol Myers Squibb Co. (NYSE:BMY)
Drug development is risky business, but Bristol-Myers has protected investors by sharing that risk with other drugmakers. Its mega blockbuster Plavix was developed with Sanofi SA (ADR) (NYSE:SNY) . Bristol-Myers’ next potential blockbuster, Eliquis, was developed with Pfizer Inc. (NYSE:PFE). The company has also established a diabetes partnership with AstraZeneca plc (ADR) (NYSE:AZN), which led to the companies jointly purchasing Amylin Pharmaceuticals.

Developing drugs with a partner cuts into the potential profits, but it also shields the company from major hits if the drug fails. When Bristol-Myers has gone it alone, it hasn’t been pretty. The company purchased Inhibitex for $2.5 billion only to see the lead hepatitis C drug it got in the deal fail in the clinic.

Beyond shareholders, Bristol-Meyers treats the rest of the stakeholders with equal respect.

Like most drugmakers, Bristol-Myers has a patient assistance program to help patients pay for their medication. In 2011, the company provided 250,000 patients with free medications valued at more than $450 million.

More generally, Bristol-Myers takes its corporate responsibility seriously. In 2010, it set a series of goals to be completed by 2015, including reducing total energy use and greenhouse gas emissions by 15% and to reduce water use by 10%.

According to reviews on Glassdoor, only 68% of employees would recommend working at Bristol-Myers to a friend, although interestingly 91% approve of CEO Lamberto Andreotti. Many of the reviews complain that it’s difficult to advance in the company. Apparently everyone wants to eventually have Andreotti’s job, but doesn’t feel like that’s possible. Something for the company to work on, for sure.